Endo Pharmaceuticals Inc.'s Belbuca (buprenorphine buccal film) will join a crowded market of extended-release/long-acting opioids with its expected first quarter 2016 launch, but its formulation differences might help it stand out.
On Oct. 23, FDA approved Belbuca, a transmucosal form of the partial mu-opiate receptor agonist buprenorphine, for management of pain severe enough to require daily, around-the clock, long-term opioid treatment...